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L. METTLER, E. ALVAREZ-RODAS, and K. SEMM
Department ofObstetrics and Gynecology, University ofKiel, and Michaelis-Midwifery School, Germany
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In cases of benign lesions, pelviscopy is used in about 70% of all abdominal operations at our
Department of Obstetrics and Gynecology. From 1990 to 1992, 851 patients with myomas were
treated by surgery. In 57% pelviscopy, in 2% laparotomy, and in 1% hysteroscopic myomectomies
were treated. In 11%, a CISH (Classical Intrafascial SEMMBserrated edged macro morcellatorB
Hysterectomy) without colpotomy was applied using the operative technique of pelviscopy or la-
parotomy. The application of this new surgical technique preserves the patient’s pelvic floor
(diaphragm pelvis and urogenitalis), its blood supply, and neural function. Details of the surgical
techniques used in pelviscopic myomaenucleations are described. One hundred sixteen patients were
treated with a gonadotropin releasing hormone analogue (GnRH-a) before the pelviscopic my-
omaenucleation took place. In this study, 64 (55%) patients received 3,75 mg leuprorelin, and 52
(45%), patients 3.75 mg triptorelin. The monthly injections took place over a period of 3 to 6 months.
After 3 months, an identical reduction of the myomas of about 10% to 50% was observed in 103 pa-
tients (88%) in both therapy groups. The preservation of the uterus by this minimal invasive surgery
technique was generally accepted. No serious complications occurred.
KEY WORDS: Gonadotropin releasing hormone analogue, laparoscopy, leiomyoma,
pelviscopy, uterine fibroids, minimally invasive organ--preserving surgery
INTRODUCTION
Uterine myomas are the most common tumors of the fe-
male genital tract. Hysterectomy is the typical therapy in
patients whose families are complete. In the last decade,
operative pelviscopy had a breakthrough in the practice
of gynecology. Recent progress has been made with
the development of appropriate instrumentation.
Myomectomy appears to be a safe technique with the ad-
vantages of pelviscopic surgery. For the preservation of
the uterus, especially for those infertile women desiring
organ-preservation, minimal invasive surgery is the cur-
rent accepted operative ideal method (1-4).
Furthermore, GnRH-a can effect a shrinkage ofleiomy-
oma before a myomectomy. GnRH-a preoperative ther-
apy offers an alternative approach to hysterectomy in
patients with the multiple uterine myomas. This therapy
induces a reversible hypogonadotropic hypogonadal en-
vironment. During gonadotropin-analogue therapy the
women are amenorrheic (5-8).
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It is the aim of this paper to summarize our experience
with organ-preserving pelviscopic operative techniques
for the uterus and to evaluate this procedure as performed
in our Department of Obstetrics and Gynecology in Kiel.
MATERIAL AND METHODS
Patients
In nearly 500 patients between January 1990 and
December 1992 myomectomies were performedby pelvis-
copy and laparotomy. The patient groups were subdivided
according to age and parity. The numbers ofmyomas were
estimated by vaginal ultrasound and by pelviscopy. Only
the anterior-posterior diameters were measured in vaginal
ultrasound (Siemens, Sonoline SL-1). The location of the
myomas was described, and according to the classical di-
vision they were further subdivided into subserous, intra-
mural, and submucous myomas. Additional indications for
themyoma excision were sterility, pain and pressure symp-
toms, bleeding abnormalities, prophylactic myomectomy,
and others. Histologically we checked for leiomyomas,
adenoleiomyomas, and leiomyosarcomas. One hundred
sixteen patients with pelviscopic myomectomy were pre-218 L. METTLER et al.
treated for 3 or 6 months with GnRH-a. We compared le-
uprorelin (Enantone Gyn(R)) and triptorelin (Decapeptyl
Depot(R)). The anterior-posterior diameter ofmyomas was
measured on vaginal ultrasound scan before and after
GnRH--a therapy.
Technique
Pedunculated Myomas
Thesemyomas were resected afterendocoagulation ofthe
pedicle or after the placement of loops or staplers.
Technique for subserous myomas included:
1. Injection in the walls with a0.05% POR 8(R)*solution
2. Positioning ofa Roeder-Loop around the base of the
myoma
3. Endocoagulation of the capsule
4. Incision of the capsule
5. Myoma enucleation
6. Continuous tension on the Roeder-Loop
7. Dissection of the myoma
8. Closure of the capsule with the Roeder-Loop
Intramural myomas
The excision of these myomas up to 500 to 700 g is pos-
sible. They may interfere with embryo growth in preg-
nancy, produce uterine bleedings, and certainly give way
to hysterectomy, because of increasing pathologic symp-
toms such as pressure on the urinary bladder or rectum.
Therefore an early excision of myoma is advisable. The
necessary endoscopic surgical steps are the following:
1. Injection of two to three dosages of 10 ml of aPOR
8(R)* 0.05% solution.
2. Endocoagulation patch with the point coagulator at
100/120C.
3. Incision with the micro- or macro scissors.
4. Myoma enucleation with the myoma enucleator.
5. Final enucleation and dislocation from the uterus.
6. Endocoagulation.
7. Suture of the wound with an endosuture and extra-
corporeal knotting technique. Usually 2-4 sutures
in one layer going deep through the myometrium.
8. Myoma extraction with the morcellator.
Even myoma lying in the depth of the uterine muscle
visible by ultrasonography and not by pelviscopic in-
spection can be excised. If they compress the uterine cav-
ity, they can be an obstacle for implantation and should
be resected pelviscopically or via hysteroscopy.
Submucous myomas
In liquid hysteroscopy such myomas can be resected by
laser or by electrocoagulation (10). (*) POR 8(R) Is a va-
sopressin derivative from Sandoz.
RESULTS
Of 851 surgical procedures (as myomectomies; total ab-
dominal and vaginal hysterectomies, and CISH proce-
dures over a period of 3 years) performed for myomatous
lesions of the uterus, 482 (57%) were pelviscopic my-
omectomies. In only 18 cases was a myomectomy via la-
parotomy performed because of very large or multiple
myomas; in 8 cases a hysteroscopic or direct vaginal my-
omectomy was carried out (Table 1, Fig. 1). Pelv-CISH
means pelviscopic classical intrafascial SEMM hysterec-
tomy, Lap-CISH means laparotomic classical intrafascial
SEMM hysterectomy (11).
The average age of the patients was 43.2 years (range,
21 to 69 years). The parity reveals that 60% of the cases
are nulli,parous, and only 3.7% women had given birth to
more than 2 children. Even in perimenopausal women
with myomas and pressure symptoms we believe endo-
scopic myomectomy to be indicated.
We found infertility in 50% of the cases, pain in 18%,
and bleeding abnormalities in 16% as indication for the
endoscopic myomectomy (Fig. 2). In 16%, fibroids were
detected, but they did not present the indication for this
intervention. In 275 cases (57%), myomectomy was the
only procedure performed. In the 207 cases, other proce-
dures also were performed such as tuboplasty, endocoag-
ulation of endometriosis, ovarian cystectomy, and
adhesiolysis. We are a reference center for infertility pa-
tients, and we believe in myomaexcision at an early stage
ofmyoma development.
The combined evaluation of the vaginal and the ab-
dominal ultrasound data and the pelviscopic inspection
states the number of all myomas and size of the largest
myoma. In 70% of the cases or 2 myomas were excised
and in 30%, 3 to 6 myomas were excised. Whereas 36%
of all myomas were localized on the uterus fundus, 39%
were found on the posterior wall of the uterus. Multiple
locations occurred in26% (Fig. 3). According to their pen-
etration depth, nearly 50% of all myomas were subserous.
Table 1 Spectrum of Treatment of Uterus Myomatosus Patients
1990 to 1992, UFK KIEL
N 851 Patients (I00%)
Pelviscopic Myomenucleation 482 (57%)
Laparotomic Myomenucleation 18 (2.0%)
Hysterectomy
Pelvic CISH* 57 (6.7%)
Lap. CISH 37 (4.0%)
Abdominal 194 (23%)
Vaginal 55 (6.4%)
Hysteroscopic Myomenucleation 8 (1.0%)
*CISH indicates classical Intrafascial SEMM (serrated edged macro morcellator)
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Spectrum of Treatment
of Uterus Myomatosus Patients
1990 1992, UFK Kiel
n 851 Patients 100%
’--7O/o
conservative 60% radical 40%
Figure 1 Spectrum of treatment of uterus myomatous patients 1990
to 1992, UFK Kiel Pelviscopic treatment of pedunculated myomas.
Indications
for Pelviscopic Myoma Enucleation
n 482 Patients
18% *
(* Multiindication) 16%
Routine Finding 16%
Figure 2 Indications for pelviscopic myoma enucleation. Pelviscopic
myomectomy of subserous myomas.
Topographic Localisation
at Pelviscopic Myoma Enucleation
n 482 Patients (Myomas 1.379 100%)
Anterior Wall
Cervical Posterior Wall
Figure 3 Topographic localization at pelviscopic myoma enucleation.
Pelviscopic myomectomy in cases of
Suture-ligature techniques were used to close the wounds
in 66% of the patients and in 9%, endocoagulation after
the myoma excision. In 25% of the cases both techniques
were applied. One thousand three hundred seventy nine
myomas were removed in 482 patients. While 670 my-
omas had a mean diameter between 10 mm and 39.9 mm
(48.6%), 709 had a mean diameter between 40 mm and
110 mm (51.4%) in vaginal ultrasound. The histology
shows mainly leiomyomas and adenoleiomyomas (Table
2). In one case, in 1992, a leiomyosarcoma unexpectedly
was found on histology. After hysterectomy no additional
leiomyosarcoma was detected in the uterine specimen.
The analysis of both GnRH-a pretreated patient groups
(the 3-month treatment group compared with the 6-month
treatment group), revealed that after 3 months the treat-
ment had already reached maximum effect. Comparing
leuprorelin and triptorelin acetate, the myoma reduction
was finally 10% to 50% in both groups (Tables 3, 4 and
5). The average blood loss was < 200 mL, no transfusions
were necessary. Postoperative bleeding occurred in 5 of
482 patients and was stopped by a second-look pelvis-
copy. No laparotomy was necessary.
DISCUSSION
In Kiel, operative pelviscopyhasreplaced70% oftheclas-
sic gynecological laparotomies (9). The goal ofminimal in-
vasive surgery is to preserve organs. Postoperative sequels
such as adhesions, intestinal obstruction, chronic abdomi-
nal pain, etc. are thus decreased (9, 11) and myomectomy
seems to be a safe technique with the advantages of pelvis-
copic surgery. The postoperative recovery time is much
shorter and more comfortable, and postoperative pain is re-
duced, making it possible for patients to eat on the same day
and get up in the evening. We have seen that pretreatment
with GnRH-a is desirable in cases ofmyomas to be resected
pelviscopically. Analyzing the time taken for themyoma re-
duction, the response can be predicted in most cases as early
as 8 weeks after the first injection (2). The gonadotropin-re-
Table 2 Histological Pathomorphology
Pelviscopic Myoma Enucleations at the UFK Kiel between
January 1990 to December 1992
N 482 Patients
Size < 4 cm 4 to 10 cm Total
Histology
Leiomyoma 304 207 511
Regressive leiomyoma 267 304 571
Necrotising leiomyoma 4 56 60
Adenoleiomyoma 32 33 65
Cellular leiomyoma 63 108 171
Sarcomas 0
Total 670 709 1379220 L. METTLER et al.
Table 3 Reduction of myomas
30
25
20
Leu total
Lcuprorelin 6 mon. (n..-,34)
Percent reduction in fibroid volume
< to */, i0 30% >50%
(3%)
Leuprorelin 3 mon. (n--30) 0 14 (47 %) (3 %)
Leuprorelin total (n=64) (2’%) 28 (44 %) 29 (45 %) 6 (9 %)
Table 4 Reduction of myomas
Trip. 6 mon. (n=32)
Trip. 3 mon. (n=20)
Trip. total (n=52)
triptoreiin 6 mo,n. (n=3.2),.,
triptorelin 3 mon. (n=20)
triptorelin total (n=52) 5 (to % (2 %)
21 (66 %)
5 (25 %)
26 (50 %)
9 (28 %)
11 (55 %
20 (38 %)
1(S%)
2 (6 %)
3 (15 %)
Percent reduction in fibroid volume
< 10-% 10-30 % 10- 50 % > 50 %
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Table 5 Hormonel pretreatment
70
60
5O
40
’"30
20
10
0
1990 (n 14) 1991 (n 39) 1992 (n 63) [ total (n 116)
leu. 6 mon. trip. 6 mon. leu. 3 mon. trip. 3 mon. leu. total trip. total
1" 1990(n=14) 10 (7i.4%) 1 (7.1/o) 6""’(0 %) 3 (21.4 %) 10,,(71.4 %)
191 (n--39) 8 (20.S%) 6 (1.4%) 17 (43.6%) 8 (_2,0. %) 2g (64 %)
1,(--63) 16( %) 2 (40%),, 13 (1,%), (14,%) 2 (4 %)
total .(n=l16) 34 (29 %) 32 (28 ./o) 30 (26,.%). 20 (17., ,.%) 64 (55 /o),
4 (28.6 %)
14 (36 %)
34 (54 %’
52 t45 %)_
leasinghormoneanalogueshave potential benefits as presur-
gical medication in the management of uterine leimyomas;
we conclude that triptorelin and leuprorelin acetates have
the similar effect. The decrease in myoma volume induced
by the analogueallowed amore limited interventionand pre-
vented excessive blood loss (12, 14).
Our experience leads to the conclusion that surgical
pelviscopy can be used for management of more compli-
cated problems and can be regarded as an alternative to
laparotomy. Preoperative evaluation is crucial in deter-
mining operative strategy, according to the size, number,
and localization of myomas. In our experience, hys-
teroscopy should be systematically performed before
pelviscopy, because it allows the surgeon to differentiate
deep intramural myomas that should be treated by pelvis-
copy from submucous myomas that can be treated by hys-
teroscopy. Frequently submucous myomas are associated
with subserous or intramural myomas. In these cases, ab-
lation of the submucosal myoma has to be performed dur-
ing the same operation by operative hysteroscopy. Our
experience has shown that the mean operating time is less
than 100 minutes. No serious complications occurred in
482 patients. In 5 cases, because ofextensive bleeding and
decrease in haemoglobin, a repeat pelviscopy had to be
performed using endocoagulation and endosutures for he-
mostasis. After intramural or submucosal myomectomy,
closure of the myometrium by sutures is recommended to
prevent postoperative bleedings. A postoperative evalua-
tion of the formation of adhesion, fertility, and normal re-
productive function is being performed, and so far no case
of uterine rupture after myomectomy has occurred.
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